Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies

Recruiting

• Conditions: Early Stage (T1-T2, N0-N1,M0); Supraglottic Squamous Cell Carcinoma

• Registration Number: NCT05611515
• Lead Sponsor: Centre Hospitalier Universitaire UCLouvain Namur

Brief Summary

In this project, the investigators will realize an observational, prospective, multicentric and international clinical trial, to objectively compare patients with SSCC according to 3 arms of treatment:

* Arm 1: Radiotherapy ± chemotherapy

* Arm 2: Trans-oral Laser Microsurgery (TLM)

* Arm 3: Trans-oral Robotic Surgery (TORS)

The main goal is to evaluate the efficacy of each treatment with four classes of outcomes:

* The quality of life (QoL) before and after each treatment option, using validated questionnaires

* Oncological outcomes

* Functional outcomes

* Economical Resources

The population will include cT1-T2 /cN0-N1/M0 supraglottic squamous cell carcinoma.

The primary outcome is a Clinical Dysphagia QoL evaluation assessed by the MD Anderson Dysphagia questionnaire. Secondary outcomes include others QoL evaluation, oncological and functional measures and cost parameters. The sample size needs to reach 36 patients per arm (total 108).

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-17
• Study First Submitted: 2022-10-14
• Status Verified: 2022-11
• Study First Submitted QC: 2022-11-03
• Last Update Submitted: 2022-11-03
• Study First Posted: 2022-11-10
• Last Update Posted: 2022-11-10
• Primary Completion: 2025-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

• Diagnosis of SSCC (with histological confirmation)

  • cT1-T2 / cN0-N1/ M0 according to 8th TNM classification (UICC/AJCC)
  • WITH a Multidisciplinary Tumor Board decision according to the NCCN or European guidelines

• Diagnostic imaging (Head and neck and pulmonary CT or PET/CT, +/- IRM if needed) realized within 1 month before the study inclusion

• ≥ 18 years old and able to provide an informed consent

• ECOG/WHO performance status ≤ 2

Exclusion Criteria

• • Previous radiotherapy +/- chemotherapy treatment of the head and neck region
• Previous history of head and neck cancer within 5 years
• Prior invasive malignant disease unless disease-free for at least 5 years or more, with exception of non-melanoma skin cancer
• Non-supraglottic or unknown primary site
• Clinical and radiological signs of nodal extracapsular extension
• Significant trismus (maximum inter-incisal opening ≤ 35 mm)
• Pre-existing dysphagia not related to the cancer or the biopsy (from neurological disorders for example)
• Unable or unwilling to complete Quality of Life questionnaires
• Serious medical comorbidities or contraindication for surgery and/or radiation
• Pregnancy and lactation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical Dysphagia QoL evaluation using MD Anderson Dysphagia Index (MDADI)	1 year	Clinical Dysphagia QoL evaluation after treatment will be assessed using MD Anderson Dysphagia Index (MDADI). MDADI consists of 20 items pooled in 4 subscales: the global scale (1 item); the functional scale (5 items); the physical scale (8 items); and the emotional scale (6 items). All items are scored on a 5-point scale (1-5), where "1" corresponds to "total agreement" and "5" to "total disagreement." All except 2 items were scored such that higher scores indicated higher functioning. Responses on all domains were summed to calculate the total score (MDADI-T). The maximum score is 100, indicating high functioning, and the minimum score is 20, indicating poor functioning.

Secondary Outcome Measures

Name	Time	Method
Oncological outcomes	1 and 2 years	Disease specific survival (%)
Functional Outcomes	1 and 2 years	Need of hospitalization (yes or no; if yes, duration in days)
Quality of Life Measures with the validated European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire	baseline (before treatment), 3 - 6 - 9 - 12 - 18 - 24 months	QoL will be evaluated with the validated European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire It is composed on five functional scales (physical, performance, cognitive, emotional and social), three symptoms scale (fatigue, pain, nausea and vomiting), a global health status/QoL scale and 6 simple items for assessment of symptoms or additional problems (dyspnea, loss of appetite, insomnia, financial difficulties, constipation and diarrhea). All of the scale and single item measures range in score from 0 to 100. Regarding functional and overall health status scales, higher scores relate to better quality of life; however, for the scales of symptoms, higher scores correspond to the higher presence of this symptom and, consequently, the worse quality of life.
Quality of Life Measures with the validated European Organization for Research and Treatment of Cancer (EORTC) H&N43 questionnaire	baseline (before treatment), 3 - 6 - 9 - 12 - 18 - 24 months	QoL will be evaluated with the validated European Organization for Research and Treatment of Cancer (EORTC) H\&N43 questionnaire It comprises 43 questions about symptoms and side effects of treatment, social function, body image and sexuality. It incorporates 12 symptom scales (pain, swallowing, problems with teeth, dry month and sticky saliva, problems with senses, speech, body image, social eating, sexuality, problems with shoulder, skin problems and fear of progression) and 7 simple items (problems opening mouth, coughing, social contact, swelling in the neck, weight loss, problem with wound healing and neurological problems). All of the scales and the single item measures range in score from 0 to 100. A high score represents a high level of symptomatology or problems.
Oncological Outcomes	1 and 2 years	Distant recurrence rate (%)

Trial Locations

Locations (1)

CHU UCL Namur; 🇧🇪 Yvoir, Namur, Belgium